Public explanations of depression have often focused heavily on serotonin, but modern neuroscience has never reduced depression to a single neurotransmitter deficit. Antidepressants affect monoamine systems and also produce slower downstream changes in receptors, gene expression, stress signaling, and neural plasticity.
Ketamine helped focus attention on glutamate and synaptic plasticity because its antidepressant effects can emerge much faster than those of conventional antidepressants in selected patients. That does not mean the older treatments were based on a false mechanism; it means depression biology and antidepressant action are more complex than a one-chemical explanation.
Ketamine was developed as an anesthetic and later studied for depression. Its rapid clinical effects stimulated research into glutamatergic signaling, network function, stress-related synaptic changes, and neuroplasticity. The field is still refining how these pieces fit together.
This article explains that science in plain language. Understanding it is genuinely useful, because it clarifies both what ketamine can reasonably be expected to do and what it cannot.
A note on route and formulation. Ketamine evidence is route-specific. Much of the controlled antidepressant literature uses intravenous racemic ketamine, while FDA-approved intranasal esketamine (Spravato®) has its own trial program and REMS requirements. Some real-world telehealth studies involve sublingual ketamine. Current Vantage materials describe clinician-guided compounded racemic ketamine nasal spray. That compounded nasal formulation is not FDA-approved for any psychiatric condition, and route-matched controlled evidence is limited. Results from IV, sublingual, or esketamine studies should not be presented as expected outcomes for compounded nasal ketamine.
The Problem With the Serotonin Timeline
Start with a puzzle that troubled psychopharmacologists for decades.
When you take an SSRI, serotonin levels in the synapse rise within hours. The drug does its stated job almost immediately. Yet the antidepressant benefit does not arrive for four to eight weeks.
The delay between monoamine changes and clinical improvement is one reason researchers look beyond immediate transmitter levels to slower downstream adaptations. It does not prove that one specific downstream process is the sole therapeutic event.
Research implicates changes in synaptic function and neural plasticity among several downstream processes involved in antidepressant response. The relative contribution of these pathways in humans remains under study.
Which raises the obvious question: if the therapeutic event is synaptic remodeling, could you trigger it directly?
What Depression Looks Like in Brain Tissue
Here the picture becomes more concrete, and more hopeful.
Chronic stress and depression are associated with changes in structure and connectivity in brain regions involved in mood, cognition, and stress regulation, including prefrontal and hippocampal networks. The strongest cellular evidence for dendritic-spine loss and regrowth comes from animal models; human neuroimaging cannot directly show individual synapses forming or disappearing.
Those brain findings are biologically plausible context for symptoms such as cognitive rigidity, low motivation, and impaired emotional regulation, but they should not be used to claim that a person feels depressed because specific neurons have “retracted.”
Neural systems remain plastic throughout adulthood. Treatments and experience can alter network function, but translating cellular plasticity findings into claims about a specific patient’s recovery requires caution.
Ketamine’s Cascade: What Happens in the First Hours
One leading model of ketamine’s antidepressant action involves a cascade of glutamatergic and intracellular signaling. The sequence below is best understood as a mechanistic model strongly supported by preclinical work, not a complete map proven in humans.
1. NMDA receptor antagonism. Ketamine blocks NMDA receptors. Preclinical work suggests that effects on particular neuronal populations can alter glutamate signaling, but the exact cell-level mechanism in humans remains unsettled.
2. Changes in glutamate signaling. Some experimental models show a transient increase in cortical glutamate signaling after ketamine. Human studies support glutamatergic effects, but the size, timing, and necessity of a single “glutamate surge” are not fully established.
3. AMPA signaling. Preclinical studies indicate that AMPA-receptor activity is important to ketamine’s antidepressant-like effects. This is a major component of current models, not a patient-level biomarker used in routine care.
4. BDNF and downstream plasticity pathways. BDNF and related signaling pathways are implicated in synaptic plasticity and antidepressant response. Evidence spans animal, cellular, and human studies, with important uncertainties about exactly how these mechanisms translate to clinical benefit.
5. mTORC1 and synaptic remodeling. Animal studies show rapid changes in synaptic proteins and dendritic spines after ketamine. Human evidence supports rapid network and functional changes, but clinicians cannot observe or promise new synapse formation in an individual patient.
The clinical fact is clearer than the mechanistic details: IV ketamine and esketamine can reduce depressive symptoms rapidly in some patients. The exact biological chain producing that effect remains an active area of research.
Neuroplasticity: The Word That Actually Matters
Neuroplasticity is the brain’s capacity to physically change its own structure and connections in response to experience. It is not a wellness metaphor; it is a measurable biological process involving protein synthesis, receptor trafficking, and structural remodeling.
Ketamine appears to influence neural plasticity, but the duration and clinical meaning of any “plasticity window” in humans are not established well enough to prescribe a universal schedule of psychological work around dosing.
Neuroplasticity is a useful research concept, but it should not be turned into a marketing claim that ketamine “rewires the brain” or guarantees that therapy will work better afterward.
Ketamine’s effects can outlast the period when the drug is present in the bloodstream, suggesting downstream biological changes matter. That observation does not tell us exactly which changes are responsible or how long they last in a given patient.
Ketamine-assisted psychotherapy is an active area of research. Systematic reviews describe promising findings but substantial heterogeneity, and controlled studies have not consistently shown added benefit from psychotherapy over ketamine alone. It is more accurate to present psychotherapy as potentially useful supportive treatment than as a proven mechanism for “locking in” ketamine-induced plasticity.
Why the Effects Fade — and What That Tells Us
After a single IV ketamine dose, antidepressant effects often diminish over days to weeks. Esketamine uses repeated induction and maintenance dosing under its FDA-approved protocol. Other racemic ketamine regimens vary, and duration should not be generalized across routes.
Because clinical benefit can outlast ketamine’s acute pharmacologic presence, downstream effects clearly matter. It is speculative, however, to say that relapse occurs because newly formed synapses “retract” under stress or poor sleep; the biology of response and relapse is more complex and not fully defined.
Repeated-dose protocols are common because a single dose often has limited durability. The number, spacing, and maintenance approach differ by product, route, evidence base, clinician, and patient response. A fixed six-session course should not be presented as universal.
Psychotherapy and behavioral care remain important treatments for depression in their own right. Whether timing them specifically around ketamine produces additional antidepressant benefit is not yet established.
How Esketamine Fits In
Ketamine is a racemic mixture — it contains two mirror-image molecules, S-ketamine and R-ketamine. Esketamine is the purified S-enantiomer, which binds the NMDA receptor with higher affinity.
Esketamine, marketed as Spravato®, is an FDA-approved nasal product for treatment-resistant depression in adults and since 2025 can be used for TRD as monotherapy or with an oral antidepressant. It is subject to a REMS, must be administered in certified healthcare settings, and requires post-dose monitoring. It should not be conflated with compounded racemic ketamine nasal spray.
Mechanistic uncertainty remains. Research into ketamine metabolites, opioid signaling, inflammation, enantiomer-specific effects, and other pathways continues. The safest patient-facing conclusion is that ketamine’s rapid antidepressant mechanism is biologically plausible and actively studied, not fully settled.
What This Science Does Not Promise
Understanding the mechanism should sharpen expectations rather than inflate them.
Ketamine has reproducible rapid antidepressant effects in selected populations, while the detailed human neuroplasticity mechanism is less settled. Mechanistic elegance should never be presented as evidence that an individual patient will respond.
Ketamine also does not resolve external circumstances such as grief, relationship conflict, financial stress, unsafe environments, or occupational strain. Those issues may need psychological, social, medical, or practical interventions regardless of medication response.
Ketamine carries real risks, including sedation, dissociation, perceptual changes, increases in blood pressure and heart rate, nausea, impaired judgment and coordination, respiratory effects in some circumstances, and misuse potential. Longer-term safety data are growing, but evidence is more extensive for IV ketamine and FDA-approved esketamine than for compounded intranasal use at home. FDA has specifically warned about risks of compounded ketamine products when monitoring is inadequate.
Care Built Around the Science
Vantage Telehealth connects users with independent licensed clinicians through Impact Health USA. Current Vantage materials describe clinician-guided compounded racemic ketamine nasal spray within a broader behavioral-health model. Clinicians determine eligibility, prescribing, monitoring, and whether in-person evaluation or a different treatment setting is required. Supportive care can help patients process treatment, but Vantage should not claim that psychotherapy has been proven to magnify ketamine’s pharmacologic effect.
If you have been researching ketamine and want to talk through whether the science applies to your situation, our licensed providers are ready to have that conversation with the detail it deserves.
Learn more about ketamine therapy at Vantage
Frequently Asked Questions
What is the neurological mechanism behind ketamine’s antidepressant effect?
Ketamine is an NMDA-receptor antagonist that alters glutamatergic signaling. Leading models involve downstream AMPA signaling, BDNF-related pathways, mTORC1, and synaptic plasticity. Much of the detailed cell-level evidence comes from animal and laboratory studies, and the full antidepressant mechanism in humans remains unsettled.
How does ketamine stimulate neuroplasticity in the brain?
Preclinical studies show that ketamine can rapidly alter BDNF-related signaling, synaptic proteins, and dendritic spines. Human studies support rapid changes in brain function and connectivity, but they do not allow clinicians to observe or promise “new synapses” in an individual patient. Neuroplasticity is a research mechanism, not a guarantee of clinical improvement.
Why do ketamine’s effects appear within hours while SSRIs take weeks?
Conventional antidepressants change monoamine signaling quickly but generally require longer before full clinical benefit can be judged, likely because downstream adaptations take time. Ketamine acts through glutamatergic pathways and can produce antidepressant effects much faster in some patients. The exact reason for that speed remains an active research question.
What is the role of glutamate in ketamine’s therapeutic effect?
Glutamate is the brain’s major excitatory neurotransmitter and is central to current models of ketamine’s action. NMDA-receptor antagonism and downstream AMPA signaling appear important, but no single pathway has been established as the complete human mechanism.
How long do the antidepressant effects of ketamine last after treatment?
After a single IV ketamine dose, antidepressant benefit often diminishes over days to weeks. Esketamine uses repeated induction and maintenance dosing under its approved protocol. Durability varies by patient and route, and the same timeline should not be assumed for compounded intranasal racemic ketamine.
Is ketamine treatment a permanent fix or does it require maintenance sessions?
Ketamine is not considered a permanent cure. Some responders need repeated or maintenance treatment, while others may not. Schedules vary by formulation, route, diagnosis, and response. Psychotherapy and behavioral support can be valuable components of depression care, but added benefit from timing psychotherapy around ketamine has not been consistently demonstrated in controlled studies.
Selected References
• Reviews of ketamine’s glutamatergic and synaptic-plasticity mechanisms in depression, including Neuropsychopharmacology literature; mechanistic details remain under active study.
• Veraart JKE, et al. Ketamine-assisted psychotherapies for mental disorders: systematic review. Clinical Psychology Review. 2026.
• Simpson RJ, Juruena MF. Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: systematic review. Psychopharmacology. 2026.
• FDA. Compounded ketamine risk alerts, 2022 and 2023.
See how Vantage Telehealth can help — Get Started →
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, treatment, or a recommendation that ketamine is appropriate for any individual. Ketamine is a Schedule III controlled substance. Racemic ketamine is FDA-approved as an anesthetic, not for any psychiatric condition; psychiatric use is off-label. Compounded ketamine products, including compounded racemic ketamine nasal spray, are not FDA-approved or evaluated by FDA for safety, effectiveness, quality, or any psychiatric indication. Spravato® (esketamine) is a distinct FDA-approved product with specific depression-related indications and REMS requirements. Evidence, safety, dosing, and monitoring differ by route and formulation. Federal telemedicine rules for controlled-substance prescribing are time-sensitive and state law may impose additional requirements, including an in-person evaluation. Vantage Telehealth is not a medical provider; it is a technology platform that connects users with independent licensed clinicians through Impact Health USA. All prescribing and clinical decisions are made solely by the treating clinician. Vantage is not an emergency service. For a mental-health crisis or thoughts of suicide or self-harm, call or text 988. For an immediate life-threatening emergency, call 911.